Oleksandr Talalaiev
Research Subjects
Oleksandr Talalaiev has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Borys M. Todurov
Shupyk National Healthcare University of Ukraine, Kyiv
1 shared publication - Christoph Schmitz
Auto Tissue Berlin GmbH, Berlin, Germany
1 shared publication - Igor Mokryk
Heart Institute of the Ministry of Health of Ukraine, Kyiv, Ukraine
1 shared publication - Ihor O. Stetsyuk
Heart Institute of the Ministry of Health of Ukraine, Kyiv, Ukraine
1 shared publication - Illia Nechai
Department of Adult Cardiac Surgery, Heart Institute Ministry of Healthcare of Ukraine, Kyiv, Ukraine
1 shared publication
Latest Publications
- Open Access
- 24 September 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 25 (2) , 338-345
Natural biomaterials in the management of the aortic valve pathology. Biomedical and clinical aspects: A review
Heart valve diseases are a prevalent cardiovascular pathology worldwide, affecting nearly 2.5% of the population. Degenerative aortic stenosis is the most common form of heart valve disease. The treatment options include surgical or transcatheter procedures. There are two main categories of valve prostheses available: mechanical heart valves constructed from synthetic materials and bioprosthetic heart valves made from natural biomaterials. The choice of valve type depends on various factors, including the underlying medical condition, suitability for anticoagulation, valve durability, and the patient’s age and preferences. Mechanical heart valves have the advantage of long-term durability. However, patients receiving mechanical implants are subjected to lifelong anticoagulation therapy with an increased risk of thromboembolism and bleeding. Natural biomaterials do not require long-term anticoagulation. However, they experience degenerative changes leading to structural valve deterioration that may require reoperation. The purpose of this article is to review the role of natural biological materials used for aortic valve replacement or repair, assess their biomedical and clinical advantages and limitations, and analyze the direction and perspectives of future development.
- 24 September 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 25 (2) , 338-345
Open AccessNatural biomaterials in the management of the aortic valve pathology. Biomedical and clinical aspects: A review
Heart valve diseases are a prevalent cardiovascular pathology worldwide, affecting nearly 2.5% of the population. Degenerative aortic stenosis is the most common form of heart valve disease. The treatment options include surgical or transcatheter procedures. There are two main categories of valve prostheses available: mechanical heart valves constructed from synthetic materials and bioprosthetic heart valves made from natural biomaterials. The choice of valve type depends on various factors, including the underlying medical condition, suitability for anticoagulation, valve durability, and the patient’s age and preferences. Mechanical heart valves have the advantage of long-term durability. However, patients receiving mechanical implants are subjected to lifelong anticoagulation therapy with an increased risk of thromboembolism and bleeding. Natural biomaterials do not require long-term anticoagulation. However, they experience degenerative changes leading to structural valve deterioration that may require reoperation. The purpose of this article is to review the role of natural biological materials used for aortic valve replacement or repair, assess their biomedical and clinical advantages and limitations, and analyze the direction and perspectives of future development.